However, a numerical trend toward a decrease of sPD-L1 in IDH-mt glioma (median pre-treatment = 0.4855 ng/ml vs. before cycle 2 = 0.039 ng/ml, p = 0.138; Fig. 3d, right panel) was observed. Here, IDH1 is linked to central nervous system cancer.